AbCellera Biologics Inc.ABCLNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank63
3Y CAGR-35.1%
5Y CAGR-25.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-35.1%/yr
Quarterly compound
5Y CAGR
-25.0%/yr
Recent deceleration
Percentile
P63
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 33.94% |
| Q3 2025 | -62.31% |
| Q2 2025 | -180.46% |
| Q1 2025 | -44.42% |
| Q4 2024 | 72.41% |
| Q3 2024 | 1.57% |
| Q2 2024 | 29.37% |
| Q1 2024 | -112.68% |
| Q4 2023 | -18400.94% |
| Q3 2023 | -100.53% |
| Q2 2023 | 144.98% |
| Q1 2023 | -242.54% |
| Q4 2022 | 124.38% |
| Q3 2022 | -146.70% |
| Q2 2022 | 170.92% |
| Q1 2022 | 699.68% |
| Q4 2021 | -181.73% |
| Q3 2021 | -103.67% |
| Q2 2021 | 47.73% |
| Q1 2021 | 6526.34% |
| Q4 2020 | 143.49% |
| Q3 2020 | -114.63% |
| Q2 2020 | 3500.13% |
| Q1 2020 | -266.35% |
| Q4 2019 | 157.02% |
| Q3 2019 | -152.99% |
| Q2 2019 | -0.00% |
| Q1 2019 | 0.00% |